Previous 10 | Next 10 |
Aziyo Biologics (AZYO) announces the initiation of an observational study to provide insight into the clinical profiles, procedural details and post-implant outcomes in patients receiving Aziyo’s CanGaroo Envelope or no envelope during initial (de novo) cardiac implantable electro...
SILVER SPRING, Md., April 28, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today the initiat...
SILVER SPRING, Md., April 26, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company...
SILVER SPRING, Md., April 20, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it pla...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Aziyo Biologics, Inc. (AZYO) Q4 2020 Earnings Conference Call March 2, 2021 16:30 ET Company Participants Ronald Lloyd - Chief Executive Officer, President & Director Matthew Ferguson - Chief Financial Officer Conference Call Participants Presentation Operator Ladies and gentlemen, thank ...
Aziyo Biologics (AZYO): Q4 GAAP EPS of -$0.57 misses by $0.10.Revenue of $12.47M (+3.5% Y/Y) beats by $0.82M.Shares -0.26%.Press Release For further details see: Aziyo Biologics EPS misses by $0.10, beats on revenue
SILVER SPRING, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial re...
SILVER SPRING, Md., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company ...
News, Short Squeeze, Breakout and More Instantly...
Aziyo Biologics Inc. Company Name:
AZYO Stock Symbol:
NASDAQ Market:
– Company to begin trading under new ticker symbol “ELUT” – SILVER SPRING, Md., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”) today announced a change of the Company’s name to Elutia Inc. The rebranding ref...
Case provides first histologic evidence that CanGaroo can catalyze development of new healthy tissue layer within an existing cardiac implantable electronic device (CIED) pocket SILVER SPRING, Md., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO) (“Aziyo”...
Negotiating multiple LOIs to divest Orthopedic business CanGaroo ® RM 510(k) resubmission to the FDA remains on track SimpliDerm ® quarterly net sales up 32% year-over-year Successful transfer of Cardiovascular product distribution to LeMaitre Vascular ...